Romilkimab (Anti-IL-13 & IL-4)

Catalog No.A4018

Technical Data

CAS No.	1399584-78-1
Source	CHO
Storage (From the date of receipt)	-80℃

Biological Activity

Description	Romilkimab is a humanized bispecific immunoglobulin-G4 antibody that targets and neutralizes IL-4 and IL-13, effectively downmodulating the inflammatory response. Its treatment significantly reduces thymus and activation-regulated chemokine (TARC) levels in patients with idiopathic pulmonary fibrosis (IPF) and significantly decreases the modified Rodnan skin score (mRSS) in patients with diffuse cutaneous systemic sclerosis (dcSSc). MW: 198.16 KD.

Description

Romilkimab is a humanized bispecific immunoglobulin-G4 antibody that targets and neutralizes IL-4 and IL-13, effectively downmodulating the inflammatory response. Its treatment significantly reduces thymus and activation-regulated chemokine (TARC) levels in patients with idiopathic pulmonary fibrosis (IPF) and significantly decreases the modified Rodnan skin score (mRSS) in patients with diffuse cutaneous systemic sclerosis (dcSSc). MW: 198.16 KD.

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

Specific storage and handling information for each product is indicated on the product datasheet. Most Selleck products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage.
We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.